

**Centers for Disease Control and Prevention**  
National Center for Immunization and Respiratory Diseases



## Vaccine Safety

Chapter 4

September 2018

Photographs and images included in this presentation are licensed solely for CDC/NORIPD online and presentation use. No rights are implied or extended for use in printing or any use by other CDC COs or any external audiences.

---

---

---

---

---

---

---

---

---

---

### Comparison of 20th Century Annual Morbidity and Current Morbidity: Vaccine-Preventable Diseases

Disease	20th Century Annual Morbidity <sup>†</sup>	2014 Reported Cases <sup>††</sup>	Percent Decrease
Diphtheria	21,053	1	> 99%
Measles	530,217	628	> 99%
Mumps	162,344	1,151	99%
Pertussis	200,752	32,971	86%
Polio (paralytic)	16,316	0	100%
Rubella	47,745	8	> 99%
Congenital Rubella Syndrome	152	0	100%
Tetanus	580	21	96%
<i>Haemophilus influenzae</i>	20,000	27*	> 99%
Total	999,159	34,807	97%
Vaccine Adverse Events	Not available	~30,000	Not available

† JAMA. 2007;298(16):2195-2193.  
†† CDC. MMWR. January 9, 2015 / 63(3):ND-733-ND-746. (MMWR 2014 provisional week 53 data)  
\* *Haemophilus influenzae* type b (Hb) < 5 years of age. An additional 12 cases of Hb are estimated to have occurred among the 226 reports of Hb (< 5 years of age) with unknown serotype.

---

---

---

---

---

---

---

---

---

---

### Importance of Vaccine Safety

- Vaccinations universally recommended or mandated
- Ongoing safety monitoring needed for the development of sound policies and recommendations

---

---

---

---

---

---

---

---

---

---

### Importance of Vaccine Safety

- Decreases in disease risks and increased attention on vaccine risks
- Public confidence in vaccine safety is critical
  - Higher standard of safety is expected of vaccines
  - Vaccinees generally healthy (vs. ill for medications)
  - Lower risk tolerance = need to search for rare reactions
  - Vaccination universally recommended and mandated

---

---

---

---

---

---

---

---

### What is "Safe"?

- SAFE = No harm from the vaccine?  
No vaccine is 100% safe
- SAFE = No harm from the disease?  
No vaccine is 100% effective
- Remind parents that to do nothing is to take a risk

---

---

---

---

---

---

---

---

### Pre-licensure Vaccine Safety Studies

- Laboratory
- Animals
- Humans



---

---

---

---

---

---

---

---

### Pre-Licensure Human Studies

- Phase I, II, III trials
- Phase III trials usually include a control group which receive a placebo
- Common reactions are identified
- Most Phase III trials include 2,000 to 5,000 participants
- Largest recent Phase III trial was REST (rotavirus) – around 70,000 infants

---

---

---

---

---

---

---

---

### Post-Licensure Surveillance

- Identify rare reactions
- Monitor increases in known reactions - Identify risk factors for reactions
- Identify vaccine lots with increased rates of reactions
- Identify “signals”—reports of adverse events more numerous than would be expected

---

---

---

---

---

---

---

---

### Vaccine Adverse Event Reporting System (VAERS)

- Jointly administered by CDC and FDA
- National reporting system
- Receives ~30,000 reports per year
- Passive—depends on healthcare providers and others to report



<https://vaers.hhs.gov/index>

---

---

---

---

---

---

---

---

### Vaccine Adverse Event Reporting System (VAERS)

- **Detects:**
  - New or rare events
  - Increases in rates of known events
  - Patient risk factors
- **VAERS cannot establish causality**
  - Additional studies required to confirm VAERS signals and causality
- **Not all reports of adverse events are causally related to vaccine**
- **Reportable Events Table (Pink Book Appendix D-2)**

---

---

---

---

---

---

---

---

### Post hoc ergo propter hoc

“After this therefore because of this”

- Temporal association does not prove causation
- Just because one event follows another does not mean that the first caused the second

---

---

---

---

---

---

---

---

### Elements Needed To Assess Correlation of Vaccine Adverse Events

	<u>Disease</u>	<u>No disease</u>
<u>Vaccine</u>	a	b
<u>No vaccine</u>	c	d

$$\frac{\text{Rate in "vaccine" group}}{\text{Rate in "no vaccine" group}} = \frac{a / a + b}{c / c + d}$$

If the rate in “vaccine” group is higher than the rate in the “no vaccine” group, then vaccines may be the cause

---

---

---

---

---

---

---

---

**Risk of Autism Spectrum Disorder (ASD)  
Among Children in Denmark, 1991-1998**

	<u>ASD</u>	<u>No ASD</u>	
<u>Vaccine</u>	345	440,310	
<u>No vaccine</u>	77	96,571	
Risk in "vaccine" group	=		$\frac{7.83}{10,000}$
Risk in "no vaccine" group			$\frac{7.96}{10,000}$
Relative Risk = 0.98			

Madsen et al. N Eng J Med 2002;347:1477-82

---

---

---

---

---

---

---

---

---

---

**Post-Licensure Vaccine Safety Activities**

- Phase IV Trials
  - ~10,000 participants
  - Better but still limited
- Vaccine Safety Data Link
- Clinical Immunization Safety Assessment Project (CISA)

---

---

---

---

---

---

---

---

---

---

**Vaccine Safety Datalink**

- Vaccine Safety Datalink:
  - Large linked databases
  - Connects vaccination and health records
  - Partnership with large health plans: population under "active surveillance"
    - 9 HMOs
    - 3% (~10 million) of U.S. population
- Plans, executes immunization safety studies
- Investigates hypotheses from medical literature, VAERS reports, changes in schedules, introduction of new vaccines

---

---

---

---

---

---

---

---

---

---



- Improve understanding of vaccine safety issues at individual level
- Evaluate individual cases with adverse health events
- Develop strategies to assess individuals
- Conduct studies to identify risk factors

---

---

---

---

---

---

---

---

### Vaccine Injury Compensation Program

- Established by National Childhood Vaccine Injury Act (1986)      ▪ Picture of website
- “No fault” program
- Covers all routinely recommended childhood vaccines
- Vaccine Injury Table (Appendix D-5,D-6)

Vaccine Injury Compensation Program website: [www.hrsa.gov/vaccinecompensation/index.html](http://www.hrsa.gov/vaccinecompensation/index.html)

---

---

---

---

---

---

---

---

### The Provider’s Role

- Immunization providers can help ensure the safety and efficacy of vaccines through proper:
  - Vaccine storage and handling
  - Timing and spacing of vaccine doses
  - Screening of contraindications and precautions
  - Patient/parent education—benefit and risk communication
  - Vaccine administration
  - Management of adverse reactions
  - Documentation
  - Reporting to VAERS as needed

---

---

---

---

---

---

---

---

## Common Concerns

---

---

---

---

---

---

---

---

**Childhood Immunization Schedule and Safety**

- **National Academy of Medicine–Mission**
  - Review scientific findings and stakeholder concerns related to the safety of the recommended childhood immunization schedule
  - Identify potential research approaches, methodologies, and study designs that could inform this question
  - Issue a summary report
- **Findings**
  - Committee finds no evidence that the schedule is unsafe
  - Following the complete childhood immunization schedule is strongly associated with reducing vaccine-preventable diseases
  - Committee calls for continued study of the immunization schedule using existing data systems

[www.iom.edu/childimmunizationschedule](http://www.iom.edu/childimmunizationschedule)

---

---

---

---

---

---

---

---

**National Academy of Medicine, August 2011**

- **Committee findings:**
  - CAUSAL RELATIONSHIP between some vaccines and adverse events
    - MMR, VZV, Influenza, etc., and anaphylaxis
  - REJECTION OF 5 RELATIONSHIPS
    - Including MMR and autism, TIV and asthma
- **Overall, the committee concluded that few health problems are caused by, or clearly associated with, vaccines**

<http://nationalacademies.org/HMD/Reports/2011/Adverse-Effects-of-Vaccines-Evidence-and-Causality.aspx>

---

---

---

---

---

---

---

---

**Multiple Vaccines**

- **Early vaccination is important to prevent diseases**
- **Vaccines are given at a young age because infants and children are at highest risk of getting sick or dying if they get these diseases**
- **Newborn babies have antibodies to some diseases from their mothers**
  - However, this immunity lasts a few months—passive immunity
  - Most babies do not get protective antibodies against diphtheria, whooping cough, polio, tetanus, hepatitis B, or Hib from their mothers. This is why it's important to vaccinate a child before she or he is exposed to a disease.

---

---

---

---

---

---

---

---

**Multiple Vaccines**

- **Babies are exposed to thousands of germs and other antigens in the environment from the time they are born**
  - When a baby is born, his or her immune system is ready to respond to the many antigens in the environment and the selected antigens in vaccines
  - Vaccines contain weakened or killed versions of the germs that cause a disease
- **Getting multiple vaccines at the same time has been shown to be safe**
  - The recommended vaccines have been shown to be as effective in combination as they are individually
- **ACIP childhood vaccine schedule ensures children get the best protection**

---

---

---

---

---

---

---

---

**Vaccine Adjuvants**

- **An adjuvant is a substance that is added to a vaccine to increase the body's immune response to the vaccine**
  - Vaccines containing adjuvants are tested for safety in clinical trials before they are licensed for use in the United States, and they are continuously monitored by CDC and FDA
- **Adjuvants have been used safely in vaccines for many decades**

---

---

---

---

---

---

---

---

### Vaccine Adjuvants

- Only some vaccines contain adjuvants including hepatitis A, hepatitis B, diphtheria-tetanus-pertussis (DTaP, Tdap), Haemophilus influenzae type b (Hib), human papillomavirus (HPV), one influenza vaccine and pneumococcal and recombinant zoster vaccine

---

---

---

---

---

---

---

---

### Autism and Vaccines

- Multiple population-based studies have examined the rate of autism among vaccinated and unvaccinated children
- Available evidence does not indicate that autism is more common among children who receive MMR or thimerosal-containing vaccines than among children who do not receive vaccines

<http://www.cdc.gov/vaccinesafety/Concerns/Autism/Index.html>

---

---

---

---

---

---

---

---

### Studies of Autism and Vaccines\*

- Kaye JA, et al. Measles, mumps, and rubella vaccine and incidence of autism recorded by general practitioners: a time-trend analysis. *Brit Med J* 322:460-463, 2001.
- Madsen KM, et al. A population-based study of measles, mumps, and rubella vaccination and autism. *N Engl J Med*. 2002;347:1477-1482.
- Frambonne E, et al. Pervasive developmental disorders in Montreal, Quebec, Canada: prevalence and links with immunizations. *Pediatrics* 118:e139-50, 2006.
- Thompson WW, et al. Early thimerosal exposure and neuro-psychological outcomes at 7 to 10 years. *N Engl J Med* 2007; 357(13):1281-92.
- Schechter R, Grether JK. Continuing increases in autism reported to California's developmental services system: mercury in retrograde. *Arch Gen Psychiatry* 2008;65(1):19-24.
- Taylor LE, Swerdfeger AL, Eslick GD. Vaccines are not associated with autism: An evidence-based meta-analysis of case-control and cohort studies. *Vaccine*. 2014 June;32(29):3623-3629

\*Partial listing of representative studies

---

---

---

---

---

---

---

---

